why was ipamorelin discontinued Comment “curious” for the full newsletter. 👇 The universe of muscle-building why was ipamorelin discontinued Peptide

Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions

Sermorelin compared to lifestyle interventions Growth hormone optimization through sermorelin should complement rather than replace foundational health practices

What does it do

Mitochondrial Biogenesis: It increases the number and activity of mitochondria within muscle cells

You read that correctly